ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于董事会、监事会延期换届的提示性公告 | 2024-09-04 | Chinese | |
| 2024年半年度报告（更新前） | 2024-08-29 | Chinese | |
| 关于作废2021年限制性股票激励计划部分已授予尚未归属的第二类限制性股票的公告 | 2024-08-29 | Chinese | |
| 2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 2024-08-29 | Chinese | |
| 董事会决议公告 | 2024-08-29 | Chinese | |
| 上海荣正企业咨询服务（集团）股份有限公司关于睿智医药科技股份有限公司2021年限制性股票激励计划作废部分限制性股票相关事项之独立财务顾问报告 | 2024-08-29 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 36041467 | 关于董事会、监事会延期换届的提示性公告 | 2024-09-04 | Chinese | ||
| 36041455 | 2024年半年度报告（更新前） | 2024-08-29 | Chinese | ||
| 36041407 | 关于作废2021年限制性股票激励计划部分已授予尚未归属的第二类限制性股票的公告 | 2024-08-29 | Chinese | ||
| 36041396 | 2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 2024-08-29 | Chinese | ||
| 36041388 | 董事会决议公告 | 2024-08-29 | Chinese | ||
| 36041383 | 上海荣正企业咨询服务（集团）股份有限公司关于睿智医药科技股份有限公司2021年限制性股票激励计划作废部分限制性股票相关事项之独立财务顾问报告 | 2024-08-29 | Chinese | ||
| 36041370 | 监事会决议公告 | 2024-08-29 | Chinese | ||
| 36041362 | 北京国枫律师事务所关于睿智医药科技股份有限公司2021年限制性股票激励计划作废部分限制性股票的法律意见书 | 2024-08-29 | Chinese | ||
| 36041352 | 2024年半年度报告摘要（更新前） | 2024-08-29 | Chinese | ||
| 36041344 | 关于子公司与香港理工大学签署《战略合作框架协议》的公告 | 2024-08-12 | Chinese | ||
| 36041332 | 股票交易异常波动公告 | 2024-08-05 | Chinese | ||
| 36041321 | 关于公司控股股东、董事长涉及诉讼的公告 | 2024-07-26 | Chinese | ||
| 36041314 | 关于全资子公司更名暨完成工商变更登记的公告 | 2024-07-17 | Chinese | ||
| 36041306 | 关于与华东师范大学签署《战略合作框架协议》的公告 | 2024-07-08 | Chinese | ||
| 36041297 | 2023年年度股东大会决议公告 | 2024-05-31 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.